HC Wainwright Predicts Armata Pharmaceuticals FY2026 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Armata Pharmaceuticals in a research report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $2.63 for the year, up from their prior estimate of $0.50. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2026 earnings at ($0.51) EPS and FY2027 earnings at ($1.92) EPS.

Armata Pharmaceuticals Trading Down 22.7%

Shares of Armata Pharmaceuticals stock opened at $2.99 on Tuesday. The company’s 50-day moving average price is $3.74 and its two-hundred day moving average price is $6.83. Armata Pharmaceuticals has a 52 week low of $2.74 and a 52 week high of $14.98.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.32. The company had revenue of $3.17 million for the quarter, compared to analysts’ expectations of $0.45 million. Armata Pharmaceuticals had a negative return on equity of 33.09% and a negative net margin of 1,626.27%.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Madison Asset Management LLC acquired a new stake in shares of Armata Pharmaceuticals during the 1st quarter valued at $21,583,000. BlackRock Inc. bought a new stake in shares of Armata Pharmaceuticals during the 2nd quarter worth $3,629,000. Sei Investments Co. bought a new stake in shares of Armata Pharmaceuticals during the 1st quarter worth $760,000. Empowered Funds LLC acquired a new position in shares of Armata Pharmaceuticals in the 3rd quarter worth $149,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Armata Pharmaceuticals in the 2nd quarter worth $193,000. Institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

(Get Free Report)

Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.

Featured Stories

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.